Page 1

Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 Reportstack

Reportstack Contact -

Summary 

Idiopathic Pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause. Limited to the lungs it occurs primarily in older adults’ =50 years old, with an abysmal prognosis (3-5 years following diagnosis). After decades of being an underserved therapeutic arena, the IPF treatment landscape is set to dramatically change with the anticipated approval and subsequent launch of two small molecule therapeutic options in 2015; InterMune’s Esbriet in the US and Boehringer Ingelheim’s Nintedanib globally. There is tangible excitement amongst the IPF community of changes to a therapeutic field, which was solely dominated by the off-label drug N-acetylcysteine for symptomatic relief and costly supportive palliative care. The IPF market (defined as the US, France, Germany, Italy, Spain, and the UK) within the five-year forecast period (2012–2017) is projected to undergo exponential growth with a steep increase in treatment uptake, particularly in the US, Italy and Spain. Also detailed, is future (past 2017) insight into highly anticipated novel targeted biologics expected to change the small molecule treatment paradigm, with the entry of STX-100 (Biogen) and GS-6624 (Gilead) in the market.

Reportstack Contact -

Scope of the Report - Overview of IPF, including epidemiology, etiology, pathophysiology, symptoms and current treatment options. - Annualized IPF therapeutics market revenue, annual cost of therapies and top line 5 year forecasts to 2017. - Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the IPF therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including disease modifying drugs. - Analysis: of the current and future market competition in the global IPF therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies . Insightful review of the key industry drivers, restraints and challenges.

Reportstack Contact -

Key Findings 

Exponential Growth in the US and EU Idiopathic Pulmonary Fibrosis Markets Expected from 2012–2017 - Aligned R&D strategies are imperative for attaining access to a lucrative and underserved IPF market

- The IPF market is a vast continuum of unmet needs

- Opportunities remain for biomarkers that identify appropriate IPF patients

- Novel biologic drugs Biogen Idec’s STX-100 and Gilead’s GS-6624 that target fibrosis will alter the current IPF small molecule landscape

Reportstack Contact -

Key Benefits 

Identify the unmet needs and remaining opportunities in the IPF therapeutics market. - Develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Assess the clinical and commercial viability of promising pipeline products. - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - Drive revenues by understanding the key trends, innovative products and Contact - technologies, market andReportstack segments likely to impact the global IPF therapeutics market in future.

Companies Mentioned in this Report 


Boehringer Ingelheim

Biogen Idec

Gilead Sciences

Bristol-Myers Squibb




Reportstack Contact -

Report at a Glance 

Number of Pages – 134

Number of Tables – 34

Number of Figures – 16

Number of Companies Mentioned – 7

Number of Marketed and Pipeline Drugs Mentioned – 7

Pipeline drugs Mentioned – 6 Phase II and 1 Phase III

Companies mentioned – Intermune, Boehringer Ingelheim, Biogen Idec, Gilead Sciences, Bristol-Myers Squibb, Promedior, Sanofi, Celgene.

Markets Covered – US, UK, Germany, France, Spain, Italy.

Number of KOLs interviews: 5

Reportstack Contact -

Other Reports in Series 

OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017

Reportstack Contact -

If you are interested... 

Contact −

Sudha B



Reportstack Contact -

Idiopathic Pulmonary Fibrosis Opportunity Analysis  

Reportstack has announced a new report on OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2...

Read more
Read more
Similar to
Popular now
Just for you